Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dorzagliatin and Empagliflozin Interaction Study
NCT03790787Phase 1Completed
- Sponsor
- Hua Medicine
- Start
- Apr 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dorzagliatin in type 2 diabetes mellitus (T2DM), sponsored by Hua Medicine. Primary endpoints: Maximum Plasma Concentration (Cmax) of Empagliflozin at 10 days, Area Under the Plasma Concentration-Time Curve (AUC0-24h) of Empagliflozin at 10 days and 6 more. Started Apr 2019; status: completed.
02
Drugs
dorzagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03790787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03790787.